Prothena Corporation plc
- PRTA
- NASDAQ
- Biotechnology
- Protein Dysregulation Therapies
- Monoclonal Antibodies
$8.35
Today −1.76%Quote Oct 16, 2026, 08:00 PM UTC
−1.30%over the last month
Max drawdown −10.8%From 1-month high −7.1%3 months −3.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$428.7M
Quote Oct 16
Next earnings
Nov 5
Expected, not confirmed
Analyst target
$30.00
+259.3% from here
Floor
$8.22
1.5% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PRTAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
67
Founded
2012